IL6 and chronic obstructive pulmonary disease: In a murine model of COPD, rCC16 at 5 μg/g bodyweight resolved pathological damage in the lungs and reduced the production of TNF-α, IL-6, and IL-8 in both the serum and BALF after CS exposure [24].